Loading…
Loading…
Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Earnings and Valuation This table compares Myriad Genetics
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.